Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin in Gestational Diabetes (POEM)
NCT02947503Phase 3Recruiting
- Sponsor
- Bethesda Diabetes Research Center
- Start
- Nov 2019
- Primary completion
- Dec 2043
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of metformin in gestational diabetes mellitus (GDM) (2 arms), sponsored by Bethesda Diabetes Research Center. Primary endpoints: GDM Outcome Score (GOS) at 30 months, Type 2 Diabetes Incidence at 282 months and 1 more. Started Nov 2019; status: recruiting.
02
Drugs
metformin
03
Conditions
gestational diabetes mellitus (GDM)
Beyond the preview
Go deeper on NCT02947503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02947503.